Expert Interviews

Patrick Cooney, president of The Federal Group, says elimination of spread pricing is one of the three key elements of the PBM legislation that he believes is likely to pass during the lame-duck session of Congress after the Nov. 5 election.

Patrick Cooney, president of The Federal Group, a Washington, D.C., lobbying firm says prospects for legislation passing this year, albeit during the post-election lameduck session, are good partly because the PBM legislation would produce Medicare savings that could be put toward other uses.

A medical expert discussses examples of successful prescription digital therapeutic (PDT) implementations and their impact on patient care, managed care coverage challenges related to PDTs, strategies to improve patient access, and methods for evaluating patient outcomes and satisfaction with PDTs.

An expert in diabetes care discusses tailoring diabetes quality measures to different types of patient populations.

Paul Noble, MD, provides his final thoughts surrounding unmet needs and breakthrough strategies for detection of IPF.

A gastroenterologist speaks about patient adherence when utilizing intravenous biologics.

Dr. Seminerio talks about how she positions intravenous and subcutaneous biologics and which patients benefit from each route of administration.

Arwen Podesta, MD, discusses key factors for the successful implementation of prescription digital therapeutics (PDTs) in clinical settings and how PDT manufacturers can support this process.

Experts discuss the importance of effective patient communication regarding prescription digital therapeutics (PDTs), the need for clinician training prior to PDT implementation, and key considerations for healthcare providers when prescribing these digital interventions.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, looks to the future of myelofibrosis treatment and discusses ongoing research and the evolving therapeutic landscape.

Addressing financial toxicity associated with myelofibrosis treatment, Dr Mahmoudjafari discusses cost considerations and how lower WAC products can benefit patients.

A renowned expert examines the essential elements for developing successful diabetes quality improvement programs.

Sean M. Oser, MD, MPH, elucidates the critical role of HEDIS measurements in optimizing treatment sequencing for diabetes care.

A leading gastroenterologist highlights her initial thoughts about subcutaneous biologics.

Dr. Seminerio uncovers what excited her about IV biologics when they first came to market.

Paul Noble, MD, discusses the roles of biomarker testing and HRCT in IPF and PPF.

Arwen Podesta, MD, examines the role of photodynamic therapies in integrative care and assess how they impact patient outcomes.

Arwen Podesta, MD, details the benefit and safety of prescription digital therapeutics.

Dr Mahmoudjafari shares clinical strategies for optimizing patient outcomes and reducing the rate of adverse events and treatment discontinuations.

A clinical pharmacy manager provides insights on optimal patient monitoring practices for patients receiving treatment for myelofibrosis.

Sean M. Oser, MD, MPH, discusses how raw CGM data can personalize diabetes treatment.

Sean M. Oser, MD, MPH, describes the role of continuous glucose monitoring (CGM) data in informing the development and implementation of quality measures for diabetes care.

An expert gastroenterologist highlights what her experience has been like with subcutaneous biologics.

Dr. Jennifer Seminerio discusses what what her overall perspective with intravenous biologics in gastrointestinal diseases

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, outlines factors that inform treatment decisions for patients with myelofibrosis, including comorbidities and platelet count.

Dr Mahmoudjafari provides an overview of JAK inhibitors available for the treatment of patients with myelofibrosis.

Sean M. Oser, MD, MPH, provides an in-depth look at the use of analytics in diabetes management.

Sean M. Oser, MD, MPH, opens a discussion surrounding key considerations in diabetes management.

Arwen Podesta, MD, details the therapeutic areas in which prescription digital therapeutics (PDTs) have been studied and show the most promise, as well as some of the unmet needs in patients with mental health conditions that PDTs may be able to address.

Arwen Podesta, MD, defines what prescription digital therapeutics (PDTs) are, describes how they differ from nonprescription digital health tools, and details the FDA review process for PDTs.